Structure Therapeutics' Phase 2 data for Aleniglipron show 16% weight loss at 44 weeks with strong tolerability and no safety ...
Commercial sales and marketing agreement enhances 3RnD’s mechanistic toxicity screening panel, and expands the reach of ...
Novo Nordisk NVO and Structure Therapeutics GPCR have emerged as noteworthy companies in the obesity space. A market leader ...
5don MSN
How a tryptophan-rich allosteric communication network helps activate a major drug target receptor
A multinational research team led by researchers at Institute of Science Tokyo, RIKEN, and the University of Toronto has ...
Structure Therapeutics (GPCR) stock jumped 10% after its GLP-1 pill aleniglipron posted 16.3% weight loss, outperforming Lilly and Novo's oral candidates.
Structure Therapeutics Inc. (NASDAQ:GPCR) is among the 14 best booming stocks to buy right now. The company’s shares have gained over 130% in the past three months, with a major surge since early ...
G-protein-coupled receptors’ star has been on the rise in biotech in recent years as researchers have discovered the vast potential for GPCR-targeting drugs in treating a range of health conditions, ...
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR, “Exicure”, “the Company”), has announced the signing of a Memorandum of Understanding (MOU) with GPCR ...
Investors in Structure Therapeutics Inc (Symbol: GPCR) saw new options begin trading today, for the December 2026 expiration. One of the key data points that goes into the price an option buyer is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results